“In producing any viral vector, the transfection reagent needs to guarantee both high titre and infectivity, as well as quality, to satisfy the needs of a particular disease indication,” says Deb.

An incorrect picture of 'mRNA' COVID-19 vaccines being more effective than 'viral vector' COVID-19 vaccines was forming across APAC. We readied to overcome a threat to vaccine trust Earlier this year, ...

The AstraZeneca-Oxford vaccine, also known as AZD1222 or Covishield, operates on a viral vector platform. It employs a weakened version of a common cold virus (adenovirus), genetically modified so ...

At a recent meeting on viral vector purification held in Williamsburg, Virginia, emphasis was placed on the need to move away from purification strategies that use potentially toxic reagents (that ...

An AstraZeneca spokesperson stated ... It has been prepared using the viral vector platform. In the vaccine, a chimpanzee adenovirus - ChAdOx1 - has been modified to enable it to carry the ...

AstraZeneca’s rare disease firm Alexion ... as well as a platform designed to improve viral vector manufacturing processes. As per the agreement, Alexion will initiate a cash tender offer ...

“AstraZeneca is building an innovative portfolio of antibodies and vaccines to tackle two of the top global public health threats – serious bacterial infections and respiratory viral infections. At ...

Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its ...